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Abstract: Uveal melanoma (UM) is the most common primary intraocular tumor in adults with
high mortality. In order to improve prognosis and survival of UM patients, it is critical to inhibit
tumor progression and metastasis as early as possible after the initial presentation/diagnosis of the
disease. Sustained local delivery of antitumor therapeutics in the posterior region can potentially
achieve long-term UM inhibition, improve target therapeutic delivery to the posterior segments, as
well as reduce injection frequency and hence improved patient compliance. To address the highly
unmet medical need in UM therapy, a bioinspired in situ gelling hydrogel system composed of
naturally occurring biopolymers collagen and hyaluronic acid was developed in the present research.
Curcumin with anti-cancer progression, anti-metastasis effects, and good ocular safety was chosen
as the model therapeutic. The developed in situ gelling delivery system gelled at 37 ◦ C within
two minutes and demonstrated excellent biocompatibility and slow degradation. The curcuminloaded nanoparticle/hydrogel composite was able to sustain release payload for up to four weeks.
The optimized nanoparticle/hydrogel composite showed effective inhibition of human UM cell
proliferation. This novel nanoparticle/in situ hydrogel composite demonstrated a great potential for
the treatment of the rare and devastating intraocular cancer.
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pharmaceutics13091335

Keywords: in situ hydrogel; nanoparticle/hydrogel composite; sustained delivery; curcumin;
uveal melanoma

Academic Editors: Anuj Chauhan,
Laurence Fitzhenry, Ana Paula Serro
and Monica M. Jablonski

1. Introduction
Received: 23 June 2021
Accepted: 22 August 2021
Published: 25 August 2021

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Uveal melanoma (UM) is considered a rare disease yet the most common primary
intraocular tumor with high metastasis and lethality in adults [1,2]. Treatment modalities including globe-preserving therapies (e.g., proton beam radiotherapy, plaque brachytherapy)
and enucleation have been commonly used. Despite the aggressive treatment strategies,
a high recurrence rate, in particular following transscleral resection (up to 32.6%), has
remained a challenge [3–5]. Moreover, nearly a half of UM patients eventually developed
metastatic diseases (primarily in the liver) that are resistant to systemic chemo- and immunotherapy, leading to poor prognosis and high mortality [6]. Up to now, there has been
a lack of effective treatment to prevent UM metastasis. Accordingly, it is considered that
early detection and intervention may be critical to improve prognosis and survival of UM.
The uvea is one of the most capillary-rich tissues of the body. Most UM occurs in the
posterior segments such as choroid (~90%), iris (~5%) and ciliary body (~5%) [7,8]. Due
to the lack of lymphatic vessels in the choroid, primary UM metastasizes almost exclusively via the hematogenous route [9,10]. As a result, effective suppression of molecular
mechanisms that activate angiogenesis, tumor cell mobility and invasion, has demonstrated the potential in improving UM therapy [11–13]. For example, regulator or knockdown hypoxia-response regulating genes cyclic AMP-response-element binding protein
and hypoxia-inducible factors-1 (HIF-1), vascular endothelial growth factor (VEGF) can
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markedly decreased UM cell or tumor growth [14–18]. However, the presence of anatomical ocular barriers (e.g., cornea, blood-retina barrier) and physiological constraints (e.g.,
nasolacrimal drainage, limited capacity in the cul-de-sac of the eye) prevents about 99% of
drug administrated systemically and topically to reach the posterior segments [19]. Local
delivery of therapeutics in the posterior chamber (e.g., via intravitreal administration) can
circumvent these barriers to directly target the tumor in the posterior chamber to improve
anti-UM effect while reducing off-target toxicity. As most therapeutics require frequent
dosing due to their short half-lives in the vitreous humor, a long-acting local delivery
platform that can sustained deliver therapeutics in the posterior chamber is considered
desirable to improve therapeutic effect and patient compliance for the UM treatment.
Various nanocarriers/microcarriers with sustained drug delivery capability have
been developed in recent years for ocular use [20,21]. Due to their size, and flexible
surface functionality, nanocarriers/microcarriers offer advantages in drug delivery for the
treatment of posterior eye diseases [22,23]. However, there are disadvantages associated
with nanocarriers/microcarriers directly administrated in the posterior chamber, including
potential toxicity due to high burst drug release; rapid phagocytic clearance which may
decrease therapeutic effect; particle aggregation due to large surface area; and particle
migration which may cause ocular inflammation [23]. Currently, marketed long-acting
intravitreal implant drug products (e.g., Ozudex® , IIuvien® ) are able to sustain deliver
therapeutics in the posterior segments over weeks to months. These implant products
are administrated via either an injector/applicator with a large size needle (i.e., 22-gauge)
or surgical procedures and hence poor patient compliance. Over the past decade, in
situ gelling hydrogels that can be injected as solutions via fine needles (i.e., 30-gauge
or smaller) and transform to gels/depots at the injection site, have attracted increasing
interests due to excellent injectability and improved patient compliance [24–26]. However,
the use of synthetic polymer-based hydrogels (e.g., polystyrene, poloxamer) has limited its
applications due to concerns on biodegradability and potentially triggering inflammatory
response and influencing retinal function [25,27]. Moreover, a crosslinking initiator or
catalyst (such as a metal catalyst, or photoinitiator) or ultraviolet (UV) light is often
needed to facilitate polymer crosslinking and gelation, which raises biocompatibility
concerns [28–30]. Accordingly, it is essential to develop a biodegradable and biocompatible
in situ forming hydrogel platform that gels within seconds to minutes and is capable of
releasing payload over weeks to months.
The vitreous body is mainly composed of hyaluronic acid and different types of
collagens, primarily type II collagen [31,32]. Inspired by the natural components of the vitreous body, an in situ gelling hydrogel delivery platform composed of naturally occurring
biopolymers such as hyaluronic acid (HA) and collagen (type II) was developed to sustained release payload for UM therapy in the present research. The in situ gelling hydrogel
system provides easy administration, prolongs retention time, and prevents drug/particle
migration. Curcumin with good ocular safety was chosen as the model therapeutic. It has
been reported curcumin can regulate hypoxia-inducible factors-1α (HIF-1α) in hepatocellular carcinoma cells, pituitary adenomas, and inhibits angiogenesis in zebrafish [33–36].
Curcumin also showed anti-proliferation and down-regulation of the expression of genes
involved in apoptosis, cell proliferation and transformation against various cancers (e.g.,
breast cancer, lung cancer, colorectal cancer) [37–41]. Moreover, curcumin has been shown
to induce cell death in human UM cells via the mitochondrial pathway [42]. As curcumin
is poorly water soluble, curcumin-loaded nanoparticles with a hydrophilic coating layer
were fabricated to improve its vitreous transport and cellular uptake. The curcumin-loaded
polymeric nanoparticles were incorporated in the collagen II and HA hydrogel (CO–HA
Gel) matrix. The rheological properties, payload release as well as in vitro anti-UM effect
of the developed curcumin nanoparticle/in situ hydrogel composites were investigated.
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2. Materials and Methods
2.1. Materials
Collagen (type II) from calf articular joints was purchased from Elastic Products
Company, Inc (Owensville, MO). Sodium hyaluronate (HA, molecular weight (MW): 15
MDa) was purchased from Lifecore Biomedical (Chaska, MN, USA). Eight-arm polyethylene glycol (PEG) succinimidyl glutarate (tripentaerythritol) (8-arm PEG, MW: 20 kDa
and 40 kDa) were purchased from JenKem Technology USA (Plano, TX, USA). Picrylsulfonic acid solution (TNBS), polysorbate (Tween) 80, N-acetylcysteine (NAC), butylated hydroxytoluene (BHT), glycine (ReagentPlus® , ≥99%), dichloromethane (DCM, ACS
reagent, ≥99.5%), poly(vinyl alcohol) (PVA, 87–90% hydrolyzed, MW: 30–70 kDa), sucrose (≥99.5%), collagenase from clostridium histolyticum (1.5 kU), hyaluronidase (type II)
from sheep testes, dimethyl sulfoxide (DMSO, ACS reagent, ≥99.9%), acetonitrile (HPLC
grade, ≥99.9%), trifluoroacetic acid (TFA, HPLC grade, ≥99.0%) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Curcumin was purchased from TCI Chemicals (Portland, OR, USA). Methoxypoly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEG-PLGA,
L/G: 50/50, w/w; MW: 5 kDa/55 kDa) was purchased from PolySciTech® , Akina, Inc.
(West Lafayette, IN, USA). LIVE/DEADTM viability/cytotoxicity kit (for mammalian cells),
CyQUANT™ MTT cell viability assay, phosphate-buffered saline (PBS, pH 7.4), trypsinEDTA (0.25%) phenol red, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES,
1 M) and penicillin-streptomycin (10,000 U/mL) were purchased from Thermo Fisher
Scientific (Waltham, MA). RPMI-1640 medium (ATCC® 30-2001™) and fetal bovine serum
(FBS) (ATCC® 30-2020™) were purchased from ATCC (Manassas, VA, USA).
Human uveal melanoma (UM) cell line MP-38 (ATCC® CRL-3296) was grown and
maintained in RPMI-1640 media with 20% (v/v) FBS and 1% (v/v) penicillin-streptomycin.
Cells were cultured in an incubator supplied with 5% CO2 at 37 ◦ C. The culture medium
was replaced every 2–3 days.
2.2. Preparation of Curcumin-Loaded Nanoparticles
Curcumin-loaded polymeric nanoparticles (Cur NP) were prepared via an emulsionsolvent-evaporation method as previously reported [43]. Briefly, curcumin and mPEGPLGA (curcumin/mPEG-PLGA = 1:7.5, w/w) were dissolved in 2 mL of DCM. The organic
phase was added into 10 mL of an aqueous phase containing 1% (w/v) PVA to form a
primary emulsion. Following size reduction via probe sonication, DCM was removed by
evaporation and the residual solvent was further removed under reduced pressure. The
resultant NP suspension was then filtered using a 0.22 µm filter (polytetrafluoroethylene,
PTFE). NP was purified via ultra-centrifugation at 229,600× g for 1 h with distilled (DI)
water three times. The concentrated NP suspension was then lyophilized using sucrose as
the cryoprotectant (sucrose/NP: 25/1, w/w). The lyophilized NP was stored at 4 ◦ C until
further use.
2.3. Characterization of Cur NP
Lyophilized Cur NP was accurately weighed, and curcumin was extracted using
200 µL of DMSO followed by acetonitrile dilution to 2 mL. The sample was then filtered
using a 0.22 µm syringe filter (PTFE) and curcumin content was determined via HPLC
(Hitachi) with a ZORBAX Eclipse XDB C18 column (5 µm, 250 × 4.6 mm) (Agilent Technologies, Inc. Santa Clara, CA, USA). The HPLC mobile phase consisted of 0.1% TFA in water
and acetonitrile (40/60, v/v) with a flow rate of 1 mL/minute. The effluent was monitored
at the wavelength of 420 nm. The retention of curcumin was around 5.2 min. The detection
and quantification limits of the HPLC analytical method were 0.027 and 0.083 µg/mL,
respectively. Curcumin loading was calculated using the following Equation (1):
Dug loading (%) =

Curcumin amount in nanoparticles
× 100
Lyophilized nanoparticle weight

(1)
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The particle size and size distribution (polydispersity index, PDI), and surface charge
of NP before and after lyophilization were characterized using Zetasizer Nano ZS90
(Malvern Instruments Ltd., Malvern, UK). The backscattering angel was 173◦ with a
standard laser wavelength λ of 633 nm. The measurement of dynamic diameter (DH ) is
according to the Stokes–Einstein equation as a function of the diffusion coefficient (D),
temperature (T), and viscosity (η). The measurements were carried out in triplicate.
2.4. Fabrication of CO–HA Gels and Composites
A HA solution in PBS (10 mM, pH 7.4) (5 mg/mL) was mixed with a collagen II
solution in a phosphate buffer (20 mM, pH 7.4) (5 mg/mL) at an optimized volume ratio
of 3/1 (HA/collagen). An 8-arm PEG solution in PBS (10 mM, pH 7.4) (200 mg/mL) was
then added into the mixture at a volume ratio of 1/13.5, and the blank hydrogel (CO–HA
Gel) was formed when incubating the mixture at 37 ◦ C.
To form NP/CO–HA Gel composite, accurately weighed NP (either blank or Cur NP)
was added into the collagen II solution prior to mixing with other gel components (i.e., HA
and PEG). The NP/CO–HA Gel composite was then formed following the similar procedure described above for the blank CO–HA Gel. To form curcumin/hydrogel composite
(Cur/CO–HA Gel), a curcumin solution in ethanol (2.424 mg/mL) was mixed with the gel
components (i.e., collagen II, HA and PEG) and the mixture was then incubated at 37 ◦ C.
2.5. Rheological Study of Blank CO–HA Gels and NP/CO–HA Gel Composites
Rheological properties of blank CO–HA Gel composed of different MW PEG with or
without NP were determined using a TA Discovery HR-2 rheometer (TA Instruments, New
Castle, DE) with a cone shape geometry (40 mm, 2◦ ). After mixing three gel components
(i.e., collagen, HA and PEG) at the ratios described in Section 2.4, 800 µL of the mixture
was immediately loaded onto a sample loading plate pre-equilibrated at 25 ◦ C. The cone
shape geometry was lowered to a pre-determined gap (48 µm) to obtain a vertical side wall.
Oscillation amplitude analysis was performed at 37 ◦ C to determine a linear viscoelastic
region (LVR) at a frequency of 1 Hz. Gelling time of hydrogels was determined via time
sweep with 1 Hz frequency and 5% strain in 20 min at 37 ◦ C. Storage modulus of the CO–
HA Gel was obtained by unconfined compression measurements with oscillation frequency
ranging from 0.1 to 10 Hz at 5% strain at 37 ◦ C. The CO–HA Gel and NP/CO–HA Gel
composites were placed between a solid plate and the rheometer geometry, and freely
expanded laterally during the dynamic compression. The measurements were carried out
in triplicate.
2.6. Crosslinking Density Study
The crosslinking degree of the CO–HA Gel was calculated based on the rubber elasticity theory using experimental storage modulus G’ as reported previously [44]. The
number of elastically active junctions in the network per unit of volume (ne , mol/m3 ) was
calculated using the following Equation (2):
G 0 = ne RT

(2)

where G0 is storage modulus, R is the gas constant, and T is the absolute temperature.
2.7. Determination of Swelling Property
Disc-shaped CO–HA Gel samples were formed in a 96-well plate in triplicate. The
sample was transferred into an Eppendorf tube and weighed on a microscale (Mettler
Toledo, Greifensee, Switzerland) to obtain the initial weight (Wi ). The sample was then
immersed in saline and incubated at 37 ◦ C to allow free swelling for 48 h. The sample
was taken out and excess saline was gently removed. Fully swollen samples (Ws ) were
weighed on a microscale and lyophilized (FreeZone Triad Cascade Benchtop Freeze Dryer,
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LABCONCO, Kansas City, MO, USA). Hydrogel swelling was calculated based on mass
change percentage (%) using the following equation:
Mass increase (%) =

WS − Wi
× 100%
Wi

(3)

The weight (Wd ) of the freeze-dried hydrogels was also determined, and the equilibrium water content (EWC) was calculated using the following equation:
EWC =

Ws − Wd
Ws

(4)

2.8. Morphology/Internal Structure of Cur NP and NP/CO–HA Gel Composites
Lyophilized Cur NP was transferred to a metal substrate with double-sided carbon
tape. A thin film of Au was sputtered coated onto the NP for 30 s. The sample was then
imaged using SIGMA VP Field Emission-scanning electron microscope (FE-SEM) (ZEISS,
Oberkochen, Germany). Hydrogel samples were imaged via cryo-SEM. The blank CO–HA
Gel sample was formed and frozen in liquid nitrogen and attached to the specimen holder
of a cryo-transfer system. The sample was transferred onto a cryostage in the SEM system
and cross-sectioned, and subsequently transferred to a SEM sample stage and examined
via FE-SEM. The structure of Cur NP/CO–HA Gel composite was also examined using
cryo-transmission electron microscopy (cryo-TEM). Small pieces of Cur NP/CO–HA Gel
composite were transferred on a TEM copper grid. The grid was quickly immersed in liquid
ethane. The frozen-hydrated specimens were mounted on a cryo-holder and observed
using JEM-2100 TEM (JEOL USA, Inc, Peabody, MA, USA). The obtained images were
analyzed by image J find edge process and threshold. The % of mesh area and mesh size
were analyzed by area fraction and ferret’s diameter function, respectively. Mesh size
diameters D90 , D50 , and D10 were obtained by excel percentile function. Diameter span
was calculated using the following equation:
Span =

D90 − D10
D50

(5)

2.9. In Vitro Degradation Study
In vitro degradation of CO–HA Gels was investigated by incubating formed hydrogels
(300 µL) in 300 µL of saline at 37 ◦ C in triplicate. At pre-determined time intervals, the
hydrogels were removed and gently washed with DI water. The remaining free amine
groups in the hydrogel were determined using a spectrophotometric method [45,46]. Briefly,
187 µL of 0.1% (w/v) TNBS diluted with 0.1 M NaHCO3 were added into the hydrogel
samples and incubated for 2 h at 37 ◦ C. The reaction was ceased by adding 563 µL of 6 N
HCl to the samples followed by autoclave for 1 h at 120 ◦ C. After the samples were cooled
down to room temperature, the mixture was then spectrophotometrically measured at
an absorbance wavelength of 340 nm using a microplate-reader (Spectramax M2 MultiMode microplate reader, Molecular Devices, LLC, San Jose, CA, USA). The free amine
group content was calculated based on a standard curve prepared using glycine standards.
The total free amine group content (ConTotal ) was determined using the same amount of
collagen II prior to the degradation study. Percentage (%) of free amine groups in the
formed hydrogel was calculated based on the Equation (6):
Free amine group (%) =

ConSample
× 100%
Con Total

(6)

In vitro degradation of CO–HA Gels (300 µL) was also studied in the presence of
enzymes, including 22.5 U (75 U/mL) collagenase and 5 U (16.7 U/mL) hyaluronidase
in 300 µL of saline at 37 ◦ C in triplicate. The hydrogels incubated in saline without the
presence of enzymes at 37 ◦ C were studied as control group.
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2.10. In Vitro Release Study of Cur NP/CO–HA Gel Composites
In vitro curcumin release characteristics from Cur NP/CO–HA Gel composites were
studied in triplicate. The composite (200 µL) was immersed in 200 µL of saline containing
10% (w/v) Tween 80, 0.1% (w/v) NAC, and 0.01% (w/v) BHT, and incubated at 37 ◦ C in a
water bath with shaking at 45 rpm. At pre-determined time points, 150 µL of release media
was withdrawn and replenished with fresh media. The released curcumin amount was
analyzed by HPLC. The percentage of cumulative curcumin released was calculated.
2.11. In Vitro Anti-UM Study of Cur NP/CO–HA Gel Composites
Anti-UM study of Cur NP/CO–HA Gel composite was conducted by using transwell
insert (6.5 mm diameter with 8.0 µm pore polyester membrane, Corning Life Sciences,
Corning, NY, USA). MP-38 cells were seeded in a 24-well plate (8 × 104 cells per well) and
incubated for 24 h till confluency reached around 80%. Cur NP/Gel 1, BLK NP/Gel 1,
Cur/Gel 1 and Cur NP suspension (curcumin concentration: 201.0 µg/mL) were tested.
The gel mixture (100 µL) was transferred into a transwell insert chamber and incubated in
a 37 ◦ C incubator to form the composites. The insert was then placed in the 24-well plate
seeded with MP-38 cells and completely immersed in the culture medium. For the Cur
NP suspension group, 100 µL of suspension (without hydrogel components) was added
into a transwell insert before the insert was placed into a 24-well plate. The cells seeded
on the 24-well plate with the transwell inserts containing different treatments were then
cultured at 37 ◦ C for 3 days. Following the treatment, the transwell inserts were removed
and cells were washed with PBS three times. CyQUANT® MTT reagents (Thermo Fisher
Scientific, Waltham, MA, USA) were prepared and added into the 24-well plate following
the manufacturer’s protocol. The absorbance of the samples at 570 nm was determined
using a microplate reader. MP-38 cells without any treatment grown in the RPMI-1640
medium were studied as control. Cell viability was calculated based on the equation below:

Cell viability (%) =

ODsample
ODControl



× 100%

(7)

In order to further demonstrate the anti-UM effect was due to the sustained curcumin
release from the NP/CO–HA Gel composites, MP-38 cells were directly cultured on the
surface of the CO–HA Gels and BLK NP/CO–HA Gel composites. MP-38 cells directly
grown in a culture plate without Gels was studied as control. Tested composites (40 µL)
were mixed at the ratios described in Section 2.4 and transferred into a 96-well plate. The
96-well plate was incubated at 37 ◦ C for 30 min. After the CO–HA Gel and composites were
well formed, 150 µL of RPMI-1640 medium without FBS was added into the wells and incubated for 2 h at 37 ◦ C. The medium was then removed and replaced with 150 µL of fresh
RPMI-1640 medium contained 20% FBS and 1% penicillin-streptomycin before seeding
MP-38 cells (1.5 × 104 cell per well) on the surface of the CO–HA Gel or blank NP/CO–HA
Gel composites. At pre-determined timepoints, cells were stained with LIVE/DEAD assay
following the manufacturer’s instruction and imaged by EVOS® FL Auto Cell Imaging System (Thermo Fisher Scientific, Waltham, MA, USA) via GFP, TexasRed, and Transmission
channels. Cell number was quantified by Image J. Cell viability was calculated based on
the equation below:
!
Cell number Live (GFP)
Cell viability (%) =
× 100%
(8)
Cell number Live (GFP) + Cell number Dead (TxRed)
2.12. Statistical Analysis
All data was collected and presented as mean ± S.D. (standard deviation). Statistical analysis was performed using Student’s t-test with p < 0.05 as the minimal level
of significance.

3. Results and Discussion
3.1. Characteristics of NP
Pharmaceutics 2021, 13, 1335
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The mechanical properties of CO–HA Gels and NP/Gel composites were studied
using unconfined compression testing. All the testing samples were evaluated in a LVR
(0.5% to 20% strain). The average storage moduli of Gel 1 and Gel 2 determined based
on the oscillation frequency method were 182.26 ± 3.93 and 166.84 ± 20.26 Pa (p > 0.05),
respectively (Figure 4a,b). The presence of NP had a stronger effect on the storage modulus
(69.54 ± 10.10 Pa) of the NP/Gel 2 composite, compared to that (148.96 ± 19.15 Pa) of
the NP/Gel 1 composite. The crosslinking density of Gel or its NP/Gel composite was
calculated based on their storage moduli. Gel 2 had a slightly lower crosslinking density
(0.064 ± 0.008 mol/cm3 ) than Gel 1 (0.071 ± 0.002 mol/cm3 ), which can be explained
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by the less functional succinimidyl groups present in the higher MW PEG. Overall, the
presence of NP resulted in a decrease in crosslinking density for both NP/Gel 1 and
NP/Gel 2 composites (0.058 ± 0.007 mol/cm3 and 0.027 ± 0.004 mol/cm3 , respectively).
The presence of NP in the Gel mesh matrix may increase distance between polymer
chains, thus decreasing the storage modulus [50]. The Gel 2 composite with a higher
MW had higher collagen mobility and less reactive groups [26]. The presence of NP9 may
Pharmaceutics 2021, 13, x FOR PEER REVIEW
of 19
further inhibit crosslinking, resulting in significant decrease in the storage modulus of the
Gel 2 composite.
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The mechanical properties of CO–HA Gels and NP/Gel composites were studied using unconfined compression testing. All the testing samples were evaluated in a LVR
(0.5% to 20% strain). The average storage moduli of Gel 1 and Gel 2 determined based on
the oscillation frequency method were 182.26 ± 3.93 and 166.84 ± 20.26 Pa (p > 0.05), respectively (Figure 4a,b). The presence of NP had a stronger effect on the storage modulus
(69.54 ± 10.10 Pa) of the NP/Gel 2 composite, compared to that (148.96 ± 19.15 Pa) of the
NP/Gel 1 composite. The crosslinking density of Gel or its NP/Gel composite was calculated based on their storage moduli. Gel 2 had a slightly lower crosslinking density (0.064
± 0.008 mol/cm3) than Gel 1 (0.071 ± 0.002 mol/cm3), which can be explained by the less
functional succinimidyl groups present in the higher MW PEG. Overall, the presence of
NP resulted in a decrease in crosslinking density for both NP/Gel 1 and NP/Gel 2 composites (0.058 ± 0.007 mol/cm3 and 0.027 ± 0.004 mol/cm3, respectively). The presence of NP
in the Gel mesh matrix may increase distance between polymer chains, thus decreasing
the storage modulus [50]. The Gel 2 composite with a higher MW had higher collagen
mobility and less reactive groups [26]. The presence of NP may further inhibit crosslinking, resulting in significant decrease in the storage modulus of the Gel 2 composite.
Overall, storage moduli of the CO–HA Gels and NP/CO–HA Gel composites were in
a range of 55 to 200 Pa, which was comparable to many soft tissues including the human
vitreous body (0.24–14.5 Pa) [51] and similar to the reported hydrogels studied as an artificial vitreous body [52]. In addition, our CO–HA Gel system with high viscosity (22.6 ±
2.73 Pa.s and 10.9 ± 1.59 Pa.s at 37 °C for NP/CO–HA Gel 1 and Gel 2, respectively) can
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model
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3.2.2.
Internal
Structure and Morphology of CO–HA Gels
The internal structure of CO–HA Gel 1 and Gel 2 was characterized using cryo-SEM.
As shown in Figure 5, Gel 2 showed a slightly smaller mesh area (70.66 ± 3.56%) and median mesh diameter (D50: 7.67 µ m) than Gel 1 (mesh area: 73.70 ± 2.93% and D50: 9.89 µ m,
Table 2). In addition, Gel 2 had a higher mesh size span value (1.89) than Gel 1 (span value:
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Overall, storage moduli of the CO–HA Gels and NP/CO–HA Gel composites were
in a range of 55 to 200 Pa, which was comparable to many soft tissues including the
human vitreous body (0.24–14.5 Pa) [51] and similar to the reported hydrogels studied as
an artificial vitreous body [52]. In addition, our CO–HA Gel system with high viscosity
(22.6 ± 2.73 Pa·s and 10.9 ± 1.59 Pa·s at 37 ◦ C for NP/CO–HA Gel 1 and Gel 2, respectively)
can increase the viscoelasticity of the vitreous body is unlikely cause turbulent flow in the
human vitreous humor and [51,53], thus reducing the risk of retinal re-detachment. This
indicated that the developed in situ gelling hydrogels and NP/hydrogel composites may
be well tolerated in these soft tissues. In vivo compatibility will be studied using an animal
model in the future.
3.2.2. Internal Structure and Morphology of CO–HA Gels
The internal structure of CO–HA Gel 1 and Gel 2 was characterized using cryo-SEM.
As shown in Figure 5, Gel 2 showed a slightly smaller mesh area (70.66 ± 3.56%) and median
mesh diameter (D50 : 7.67 µm) than Gel 1 (mesh area: 73.70 ± 2.93% and D50 : 9.89 µm,
Table 2). In addition, Gel 2 had a higher mesh size span value (1.89) than Gel 1 (span value:
1.46), indicating that the meshes of Gel 2 had a wider mesh size distribution. It has been
reported that the component and composition of a hydrogel and crosslinking density can
influence hydrogel mesh size [28]. Considering that the difference in crosslinking density
of Gel 1 and Gel 2 was not significant (p > 0.05), PEG MW appeared to play a significant
Pharmaceutics 2021, 13, x FOR PEER REVIEW
11 of 19
role in the mesh size distribution. The high MW PEG with a longer polymer chain may
lead to the formation of interpenetrating polymer networks and hence smaller meshes.
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The swelling property and EWC of CO–HA Gels were also studied. Overall, our CO–
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1.46 causes73.70
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of hydrogels
inevitably
decrease
Gel 2
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7.67
18.36
1.89
70.66 ± 3.56
chanical strength, morphology changes, and bulk degradation [54,55]. In addition, swollen hydrogel may cause not only slippage from the implantation or injection site but also
tissue compression [56]. Therefore, our CO–HA gel system with low swelling in the aqueous environment is considered desirable in achieving prolonged drug release while maintaining good compatibility with surrounding tissues. The calculated EWC of CO–HA Gel
1 and Gel 2 was 96 ± 0.12% and 97 ± 0.3%, respectively, which were very similar to that of
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Figure 5. Cryo-SEM images of Gel 1 (20 kDa PEG) (a,b) and Gel 2 (40 kDa PEG) (c,d). Scale bar:
11 of 19
(a,c) 40 μm; (b,d) 20 μm.
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3.3. In Vitro Degradation of CO–HA Gels
In vitro degradation behavior of CO–HA Gel 1 and Gel 2 was studied in saline at 37 ◦ C.
CO–HA Gel was formed through ester linkers between PEG and collagen II and the ester
linkers are susceptible to hydrolytic degradation. Therefore, the non-crosslinked free amine
groups determined using the TNBS assay can indirectly reflect the crosslinking degree
between PEG and collagen when compared with collagen alone [46,62]. The changes in free
amine groups of Gel 1 and Gel 2 were monitored during a 4-week degradation study. The
initial free amine group percentage of Gel 1 and Gel 2 without degradation was 3.9 ± 1.02%
and 24.4 ± 2.45%, respectively. The lower amount of free amine groups in Gel 1 than
Gel 2 confirmed the higher crosslinking degree of Gel 1 than Gel 2, which was consistent
with the crosslinking density results described in Section 3.2.1. As shown in Figure 7, the
percentage of free amine groups of both Gels gradually increased with the degradation of
the hydrogels over 4 weeks. Gel 1 and Gel 2 had 47.6 ± 1.02% and 68.0 ± 3.21% free amine
groups by day 28, respectively. There was no obvious gel structure change observed for
both Gels. These results indicated that slow degradation behavior of the developed in situ
CO–HA Gels, which can be used to achieve sustained payload release.
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Figure 7, the percentage of free amine groups of both Gels gradually increased with the
degradation of the hydrogels over 4 weeks. Gel 1 and Gel 2 had 47.6 ± 1.02% and 68.0 ±
3.21% free amine groups by day 28, respectively. There was no obvious gel structure
change observed for both Gels. These results indicated that slow degradation behavior of
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the developed in situ CO–HA Gels, which can be used to achieve sustained12 payload
release.
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com posites

BHT to minimize curcumin degradation during long-term release studies [66,67]. As
In vitro release characteristics of the Cur NP/Gel composites were studied in the presshown in Figure 8a, curcumin slowly released from the Cur NP/Gel 1 composite and about
ence of stabilizers including 10% (w/v) Tween 80, 0.1% (w/v) NAC, and 0.01% (w/v) BHT
55% curcumin was released over four weeks, whereas the Cur NP/Gel 2 composite had
to
minimizehigher
curcumin
degradation
long-term
[66,67].
As shown in
a relatively
curcumin
release induring
the first
two days,release
which studies
may be due
to higher
Figure
8a,
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slowly
released
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Cur
NP/Gel
1
composite
and
about 55%
swelling of Gel 2 and hence faster payload diffusion and higher initial curcumin release.
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was
released
over four
weeks, whereas
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2 composite
had a relaWith respect
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Cur NP/Gel
2 composite,
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slowed
down after day
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10 days.inThe
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released
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around
43% byswelling
tively
higher curcumin
thecumulative
first two days,
which
may be
to higher
the end of four weeks. Overall, the NP/Gel 1 composite showed better sustained curcumin
release behavior. This may be attributed to its higher portion of large meshes through
which payload can transport to the release medium (Table 2). In order to demonstrate
whether intact NP can be released from the composite, release samples collected were
imaged via Cryo-TEM. As shown in Figure 8c, spherical Cur NP was observed in the day-5
release samples, and the released Cur NP showed a similar particle size compared to that
of the control group (NP suspended in water) (Figure 8d). These results demonstrated that
intact Cur NP can be sustained released from our CO–HA Gels, which may lead to better
transport of curcumin in the vitreous humor to reach its target posterior site (i.e., choroid).
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Pharmaceutics 2021, 13, 1335

16 of 19

4. Conclusions
The present research developed a long-acting, injectable, in situ gelling hydrogel
delivery platform inspired by the nature components of the vitreous body. The in situ
gelling hydrogel composed of nature occurring polymers collagen and hyaluronic acid
demonstrated excellent biocompatibility and can gel within minutes at the body temperature. In addition, the in situ gelling hydrogel with low swelling and soft storage modulus
degraded slowly and was capable of sustained release payload over four weeks. More
importantly, the curcumin nanoparticle/in situ hydrogel composite demonstrated excellent
anti-UM effect in a short-term anti-UM effect study. These results demonstrated the great
potential of the developed nanoparticle/in situ hydrogel composite for sustained treatment
of uveal melanoma in the posterior chamber. The biodistribution in ocular tissues (e.g.,
choroid and retina) and anti-UM effect and safety (e.g., tissue compatibility and intraocular
pressure) of the developed Cur NP/Gel composite need to be further studied using an
animal model.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13091335/s1, Figure S1: (a) Optical transmittance spectra and (b) photo of
CO–HA Gel 1 and NP/Gel 1 composites in a 96-well plate with a 125 µm sample thickness. Water
was studied as a control. References [72,73].
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